Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta‑analysis

Dai,Dongjun; Wang,Yunliang; Wang,Lingyan; Li,Jinfeng; Ma,Qingqing; Tao,Jianmin; Zhou,Xingyu; Zhou,Hanlin; Jiang,Yi; Pan,Guanghui; Xu,Limin; Ru,Ping; Lin,Danfeng; Pan,Jun; Xu,Leiting; Ye,Meng; Duan,Shiwei

doi:10.3892/br.2014.220

Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta‑analysis

Authors:
- Dongjun Dai
- Yunliang Wang
- Lingyan Wang
- Jinfeng Li
- Qingqing Ma
- Jianmin Tao
- Xingyu Zhou
- Hanlin Zhou
- Yi Jiang
- Guanghui Pan
- Limin Xu
- Ping Ru
- Danfeng Lin
- Jun Pan
- Leiting Xu
- Meng Ye
- Shiwei Duan
View Affiliations

Affiliations: Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Neurology, 148 Central Hospital of PLA, Zibo, Shandong 255300, P.R. China, Bank of Blood Products, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China, Department of Neurology, Affiliated Hospital, Ningbo University, Ningbo, Zhejiang 315000, P.R. China
Published online on: January 13, 2014 https://doi.org/10.3892/br.2014.220
Pages: 275-281

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects ~2% of the population aged ≥65 years. The degeneration of dopamine neurons in the substantia nigra contributes to the pathogenesis of PD. Dopamine receptor D2 (DRD2) and dopamine receptor D3 (DRD3) are two key subtypes of dopamine receptors. The aim of our study was to evaluate the association between the polymorphisms of DRD2 and DRD3 genes and PD. Meta‑analyses were conducted from 16 studies (46 stages) among 4,279 cases and 5,661 controls between PD and 9 polymorphisms (DRD2: rs1800497, rs1079597, rs6278, rs6279, rs273482, rs1799732 and rs1076563; DRD3: rs6280 and rs2134655). A significant association was observed between DRD3 rs2134655 polymorphism and PD [P=0.01, odds ratio (OR)=1.17, 95% confidence interval (CI): 1.03‑1.32] and a borderline association was observed between DRD2 rs1800497 polymorphism and PD in Europeans (P=0.05, OR=1.13, 95% CI: 1.00‑1.27). Findings of the current meta‑analysis suggested that DRD3 rs2134655 polymorphism was associated with a 17% increased risk of PD and that DRD2 rs1800497 polymorphism had a potential to increase the risk of PD by 13% in Europeans. Future large‑scale studies are required to confirm the ethnic difference of DRD2 rs1800497 polymorphism and to determine whether there were significant associations of PD with other polymorphisms in DRD2 and DRD3 genes.

View Figures

View References

1	Van Den Eeden SK, Tanner CM, Bernstein AL, et al: Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 157:1015–1022. 2003.
2	Elbaz A, Bower JH, Maraganore DM, et al: Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 55:25–31. 2002.
3	Dauer W and Przedborski S: Parkinson’s disease: mechanisms and models. Neuron. 39:889–909. 2003.
4	Mylius V, Engau I, Teepker M, et al: Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 80:24–28. 2009.
5	Grachev ID: Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson’s disease with depressive symptoms: a biological marker for causal relationships? J Neurol Neurosurg Psychiatry. Jul 6–2013.(Epub ahead of print).
6	Blonder LX, Slevin JT, Kryscio RJ, et al: Dopaminergic modulation of memory and affective processing in Parkinson depression. Psychiatry Res. 210:146–149. 2013. View Article : Google Scholar : PubMed/NCBI
7	Lee JY, Kim JM, Ahn J, et al: Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord. Jun 17–2013.(Epub ahead of print). View Article : Google Scholar
8	Aarsland D, Zaccai J and Brayne C: A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 20:1255–1263. 2005.
9	Gan EC, Lau DP and Cheah KL: Stridor in Parkinson’s disease: a case of ‘dry drowning’? J Laryngol Otol. 124:668–673. 2010.
10	Klebe S, Golmard JL, Nalls MA, et al: The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry. 84:666–673. 2013.PubMed/NCBI
11	Rode J, Bentley A and Parkinson C: Paraganglial cells of urinary bladder and prostate: potential diagnostic problem. J Clin Pathol. 43:13–16. 1990. View Article : Google Scholar : PubMed/NCBI
12	Najafi MR, Chitsaz A, Askarian Z and Najafi MA: Quality of sleep in patients with Parkinson’s disease. Int J Prev Med. 4(Suppl 2): S229–S233. 2013.
13	Horvath J, Burkhard PR, Bouras C and Kovari E: Etiologies of Parkinsonism in a century-long autopsy-based cohort. Brain Pathol. 23:28–33. 2013. View Article : Google Scholar : PubMed/NCBI
14	Olanow CW and Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144. 1999.
15	Wirdefeldt K, Adami HO, Cole P, et al: Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 26(Suppl 1): S1–S58. 2011.
16	Vaglini F, Viaggi C, Piro V, et al: Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav Neurosci. 7:712013. View Article : Google Scholar : PubMed/NCBI
17	Lill CM, Roehr JT, McQueen MB, et al: Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet. 8:e10025482012.PubMed/NCBI
18	McInerney-Leo A, Hadley DW, Gwinn-Hardy K and Hardy J: Genetic testing in Parkinson’s disease. Mov Disord. 20:1–10. 2005.
19	Bekris LM, Mata IF and Zabetian CP: The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 23:228–242. 2010. View Article : Google Scholar
20	Jaber M, Robinson SW, Missale C and Caron MG: Dopamine receptors and brain function. Neuropharmacology. 35:1503–1519. 1996. View Article : Google Scholar : PubMed/NCBI
21	Noble EP: D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet. 116B:103–125. 2003. View Article : Google Scholar : PubMed/NCBI
22	Li MD, Ma JZ and Beuten J: Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet. 66:382–392. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ritz B, Ascherio A, Checkoway H, et al: Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 64:990–997. 2007. View Article : Google Scholar : PubMed/NCBI
24	Munafo M, Clark T, Johnstone E, et al: The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res. 6:583–597. 2004. View Article : Google Scholar : PubMed/NCBI
25	Oliveri RL, Annesi G, Zappia M, et al: The dopamine D2 receptor gene is a susceptibility locus for Parkinson’s disease. Mov Disord. 15:127–131. 2000.
26	Grevle L, Guzey C, Hadidi H, et al: Allelic association between the DRD2 TaqI A polymorphism and Parkinson’s disease. Mov Disord. 15:1070–1074. 2000.PubMed/NCBI
27	Costa-Mallen P, Costa LG, Smith-Weller T, et al: Genetic polymorphism of dopamine D2 receptors in Parkinson’s disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism. J Neurol Neurosurg Psychiatry. 69:535–537. 2000.
28	Kelada SN, Costa-Mallen P, Costa LG, et al: Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson’s disease. Neurotoxicology. 23:515–519. 2002.PubMed/NCBI
29	Tan EK, Tan Y, Chai A, et al: Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson’s disease. Mov Disord. 18:593–595. 2003.
30	Chen X: The association between cigarette smoking and genes and Parkinson’s disease. Capital Med Univ; 2006, (In Chinese).
31	Singh M, Khan AJ, Shah PP, et al: Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem. 312:131–138. 2008. View Article : Google Scholar : PubMed/NCBI
32	Li W: Correlation study between dopamine D2 receptor gene TaqI polymorphism and Parkinson’s disease. J Clin Psyc Med. 21:3192009.PubMed/NCBI
33	Lee JY, Lee EK, Park SS, et al: Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 24:1803–1810. 2009.PubMed/NCBI
34	Kiyohara C, Miyake Y, Koyanagi M, et al: Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson’s disease in a Japanese population. BMC Neurol. 11:892011.
35	Lee JY, Cho J, Lee EK, et al: Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 26:73–79. 2011.PubMed/NCBI
36	McGuire V, Van Den Eeden SK, Tanner CM, et al: Association of DRD2 and DRD3 polymorphisms with Parkinson’s disease in a multiethnic consortium. J Neurol Sci. 307:22–29. 2011.
37	Nanko S, Hattori M, Ueki A and Ikeda K: Dopamine D3 and D4 receptor gene polymorphisms and Parkinson’s disease. Lancet. 342:2501993.
38	Nanko S, Ueki A, Hattori M, et al: No allelic association between Parkinson’s disease and dopamine D2, D3, and D4 receptor gene polymorphisms. Am J Med Genet. 54:361–364. 1994.
39	Higuchi S, Muramatsu T, Arai H, et al: Polymorphisms of dopamine receptor and transporter genes and Parkinson’s disease. J Neural Transm Park Dis Dement Sect. 10:107–113. 1995.
40	Wang J, Liu ZL and Chen B: Polymorphisms of dopamine D3 receptor gene and Parkinson’s disease. Chin J New Drugs and Clin Remedy. 19:108–109. 2000.
41	Button KS, Ioannidis JP, Mokrysz C, et al: Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 14:365–376. 2013. View Article : Google Scholar : PubMed/NCBI
42	Xu WD, Zhou M, Peng H, et al: Lack of association of IL-6 polymorphism with rheumatoid arthritis/type 1 diabetes: A meta-analysis. Joint Bone Spine. 80:477–481. 2013. View Article : Google Scholar : PubMed/NCBI
43	Tao JH, Zou YF, Feng XL, et al: Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol Biol Rep. 38:4663–4672. 2011. View Article : Google Scholar : PubMed/NCBI
44	Excoffier L, Laval G and Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 1:47–50. 2005.PubMed/NCBI
45	Coory MD: Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
46	Kawalec P, Mikrut A, Wisniewska N and Pilc A: The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 32:1415–1424. 2013. View Article : Google Scholar : PubMed/NCBI
47	Gibson E, Fenster A and Ward AD: The impact of registration accuracy on imaging validation study design: A novel statistical power calculation. Med Image Anal. 17:805–815. 2013. View Article : Google Scholar : PubMed/NCBI
48	Thompson J, Thomas N, Singleton A, et al: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 7:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
49	Noble EP: The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol. 16:33–45. 1998. View Article : Google Scholar : PubMed/NCBI
50	Talkowski ME, Mansour H, Chowdari KV, et al: Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry. 60:570–577. 2006. View Article : Google Scholar : PubMed/NCBI